Furthermore, spatially exclusive relationships between LRFN2+ tumor cells and CD8+ T cells, as well as markers such as programmed cell death-1 (PD-1) and T cell factor 1 (TCF-1), have been observed, thereby enhancing tumor resistance (Yu et al., 2023). The gene discussed is LRFN2; the disease is neoplasm.